TRAVATAN Z's oppositions filed in EPO
TRAVATAN Z Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5510383 | SANDOZ | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
Aug, 2013
(10 years ago) | |
| US5889052 | SANDOZ | Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension |
Dec, 2014
(9 years ago) | |
| US8323630 | SANDOZ | Self-preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8388941 | SANDOZ | Self preserved aqueous pharmaceutical compositions |
Sep, 2027
(3 years from now) | |
| US8268299 | SANDOZ | Self preserved aqueous pharmaceutical compositions |
Oct, 2029
(5 years from now) | |
Travatan Z is owned by Sandoz.
Travatan Z contains Travoprost.
Travatan Z has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Travatan Z are:
- US5510383
- US5889052
Travatan Z was authorised for market use on 21 September, 2006.
Travatan Z is available in solution/drops;ophthalmic dosage forms.
Travatan Z can be used as method for treating glaucoma and ocular hypertension.
The generics of Travatan Z are possible to be released after 13 October, 2029.
Drugs and Companies using
TRAVOPROST ingredient
Market Authorisation Date:
21 September, 2006Treatment:
Method for treating glaucoma and ocular hypertensionDosage:
SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of TRAVATAN Z before its drug patent expiration?
More Information on Dosage
TRAVATAN Z family patents
